|Articles|April 11, 2022
- Pharmaceutical Executive-04-01-2022
- Volume 42
- Issue 4
Pharmaceutical Executive, April 2022 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive April 2022 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 3 years ago
Seven Lessons I Learned Working at a Biotech Startupover 3 years ago
Next-Gen Partnerships: The Ascent of Advanced Therapiesover 3 years ago
Advantage Pharma: Capitalizing on Workforce Lessonsover 3 years ago
Diversity in Action: Q&A With Reshma Kewalramaniover 3 years ago
Diversity in Action: Q&A With Bob McMahonover 3 years ago
A Dogged Devotionover 3 years ago
Surviving Biotech’s Longest and Steepest Bear Market Everover 3 years ago
The Case for Elevating a Brand’s Price Propositionover 3 years ago
The Impact of Hybrid Workplace Decisions On DE&I DynamicsNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
2
Merck Planning $70 Billion Investment for US Expansion
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
